Novo Nordisk will spend DKK 650m ($98m) updating and expanding its facilities in Kalundborg, Denmark, which are responsible for the production of diabetes treatments.
Two of its current facilities will be entirely rebuilt to prepare for the production of the ‘next generation of products,’ according to the company. The location holds a total of 14 facilities and employs approximately 3,500 people.
Michael Hallgren, SVP for Novo Nordisk’s production in Kalundborg, told us that the rebuild will involve additional production equipment being added.
Specifically, Halligren told us, “The investment will transform the production facilities from single-line production to multi-line production leading to increase of flexibility and capacity.”
The updates to the site are expected to be completed by 2020.
According to Novo Nordisk, the Kalundborg site produces half of the world’s supply of insulin and the company has invested more than DKK 150bn in the site since 2000.
The information on which next-generation product would be processed at the updated facilities could not be provided.
As part of its announcement, Novo Nordisk provided an update on its role within the Kalundborg Symbiosis – a research-sharing partnership between six private companies and three public operators.
The agreement between the partners sees residue or by-products produced by one company be converted into a resource by another company in their production process. This has led to 22 different resources shared across the network